|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Indomethacin significantly decreased the expression of β-catenin, a key player in tumor metastasis.
|
31770037 |
2020 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Recurrence rate in patients with stage IA disease at diagnosis was significantly higher in patients whose tumors were CTNNB1 mutated compared with CTNNB1 wild-type (30% vs. 0%; P=0.025) and included distant metastases; all recurrent tumors in this group harbored exon 3 mutations and were histologically low grade (5 grade 1, 2 grade 2).
|
30702464 |
2020 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
We assessed genetic alterations (in PTEN, CTNNB1, POLE, etc) and evaluated correlations with patient outcomes to determine the utility of clonality analyses for differentiating between metastases and concurrent primary tumors and for determining whether genetic alterations in synchronous tumors are predictive of biological behavior.
|
30448219 |
2019 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Moreover, the p53/SSAT/β-catenin and PAO/ROS/GSH/GSH-Px pathways are involved in the inhibition of <b>4a</b>-induced tumor metastasis.
|
31765154 |
2019 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Targeting nuclear β-catenin as therapy for post-myeloproliferative neoplasm secondary AML.
|
30575820 |
2019 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The current study demonstrated that treatment with gefitinib decreased the protein expression levels of phosphorylated-GSK3β and β-catenin, which suggests that gefitinib may be a potential novel therapeutic strategy in CC by suppressing the Wnt/β-catenin signaling pathway and EMT to inhibit tumor metastasis in CC cells.
|
31410143 |
2019 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Our analysis revealed that ADQ was sufficiently and specifically interfering HOTAIR/EZH2 interaction, thereby impairing the H3K27-mediated tri-methylation of NLK, the target of HOTAIR gene, and consequently inhibiting tumor metastasis through Wnt/β-catenin pathway in vitro and in orthotopic breast cancer models.
|
30764859 |
2019 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
The present work examines whether these actions are associated with changes in the expression of cadherins, β-catenin and vimentin, established markers of the Epithelial-Mesenchymal Transition (EMT) which has been linked with cell migration and tumour metastasis.
|
30403907 |
2019 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Our findings identify a critical role of FMOD in cancer metastasis, reveal a mechanism regulating FMOD transcription and impacting tumor metastasis, uncover action targets and mechanism for the anticancer activity of Aspirin, and expand the understanding of the Wnt/β-catenin pathway and tumor metastasis, which are valuable for development of cancer therapeutics.
|
31824307 |
2019 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Conversely, CD99 inhibits tumor metastasis through the Wnt/β-catenin pathway.
|
31078446 |
2019 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Taken together, the study illustrates that miR-1246 regulates Wnt/β-catenin pathway through targeting GSK-3β/β-catenin, which partly contributing to tumor metastasis.
|
30913872 |
2019 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The canonical Wnt/β-catenin pathway plays essential roles in promoting tumor formation, yet its function in regulating tumor metastasis and the underlying mechanisms remain controversial.
|
30683884 |
2019 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Recent genome-wide analysis of prostate cancer metastases illustrate the importance of the Wnt/β-catenin pathway in prostate cancer and compel us to reexamine the interaction of the AR and Wnt/β-catenin signaling pathways.
|
28189566 |
2018 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
However, in early-stage SCC patients, SOX30 has no inhibitory role on tumor-metastasis due to not binding to CTNNB1 promoter leading to an unfavorable prognosis of the patients.
|
30514297 |
2018 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, upregulation of CD300A led to significant decrease in expression level of Wnt3 and β-catenin, the pivotal components in Wnt/β-catenin signaling pathway, and an increase in expression of E-cad, a key protein in tumor metastasis, in A549 and H1650 cells; while depletion of CD300A up-regulated the Wnt/β-catenin signaling pathway.
|
30573974 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Our results indicate the utility of CDK8 inhibitors for the treatment of colon cancer metastases in the liver and suggest that CDK8 inhibitors may be considered in other therapeutic settings involving TGFβ/SMAD or Wnt/β-catenin pathway activation.
|
30185549 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Pathway analysis predicted Wnt signaling to be altered during tumor progression, which was supported by decreased nuclear translocation of β-catenin in metastases.
|
29487354 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
The findings of this study suggest that miR-155 and β-catenin may have a unique potential as a novel biomarker candidate for diagnosis and treatment of tumor metastasis.
|
29364476 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
<i>Results</i>: The deletion of miR-200c/141 cluster regulated BCSC heterogeneity and promoted the EMT-like BCSC generation, which resulted in increased tumor metastasis and inhibited tumor growth by directly upregulating the target gene homeodomain-interacting protein kinase 1 (HIPK1) and sequential β-catenin activation.
|
30613263 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Unlike β-catenin that has oncogenic function through its role in the Wnt pathway, plakoglobin generally acts as a tumor/metastasis suppressor.
|
29660231 |
2018 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
Dickkopf-Related Protein 2 is Epigenetically Inactivated and Suppresses Colorectal Cancer Growth and Tumor Metastasis by Antagonizing Wnt/β-Catenin Signaling.
|
28365691 |
2017 |
|
Secondary Neoplasm
|
0.100 |
Biomarker
|
group |
BEFREE |
A structured group exercise program for patients with metastatic cancer receiving chemotherapy and CTNNB1 (β-catenin) as a biomarker of exercise efficacy.
|
29075139 |
2017 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Furthermore, overexpression of β-catenin by adenoviruses blocked these benefits of luteolin on invasion and metastases of breast cancer.
|
27959422 |
2017 |
|
Secondary Neoplasm
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Tumor genomic complexity increases with EGFR-inhibitor treatment, and co-occurring alterations in CTNNB1 and PIK3CA exhibit nonredundant functions that cooperatively promote tumor metastasis or limit EGFR-inhibitor response.
|
29106415 |
2017 |
|
Secondary Neoplasm
|
0.100 |
AlteredExpression
|
group |
BEFREE |
These findings suggest that miR-135b mediates the constitutive activation of Wnt/β-catenin and Notch signaling, and that the inhibition of miR-135b is a novel strategy to inhibit tumor metastasis and prevent CSC-induced recurrence in OS.
|
28918013 |
2017 |